Common clinical BLCA biomarkers including urinary fibrinogen/fibrin degradation products (FB/FDP), bladder tumor antigen (BTA), nuclear matrix protein 22 (NMP22), hyaluronic acid (HA), and hyaluronidase (Haase) [26–28] but these still lack accurate disease stratification for BLCA. This evidence concerns the gene NUMA1 and bladder transitional cell carcinoma.